Jenna Foger has headed up the corporate venturing activities of Alexandria – a New York-based real-estate business with a focus on the life sciences sector – since 2014. During that time, she has seen the total number of deals made by Alexandria Venture Investments rise to 175, as well as successful exits for portfolio companies including Covid-19 vaccine-maker Moderna and agtech firm Benson.
Recent investments include participation in a $500m series A round for Neumora Therapeutics, a developer of treatments for brain disease, and in a $70m series B round for protein drug developer Lycia Pharmaceuticals.
Foger recently told Leader magazine: “As the most active early-stage life science investor in New York City with over a couple dozen investments locally, I spend quite a bit of time sourcing and evaluating opportunities, identifying new syndicate partners and convening the local life science venture community through efforts such as our Seed Capital Platform.”
The Seed Capital Platform was set up in 2018 with the intention of accelerating seed funding for life sciences technology developers by bringing together participants from across the healthcare venture capital space. It followed the creation a year earlier of life science startup accelerator Alexandria LaunchLabs, which was initially based in New York City but which now has a number of locations across the US.
Prior to joining Alexandria, Foger was an associate at Windham Venture Partners, where she assisted in expanding the healthcare venture fund with a particular focus on medical technology, diagnostics, and digital health investments.
Foger also has laboratory experience as a research associate at the Rockefeller University, where she completed her masters degree in biotechnology from Columbia University.
